DZ2539A1 - Compositions pharmaceutiques pour le traitement dela résistance à l'insuline. - Google Patents

Compositions pharmaceutiques pour le traitement dela résistance à l'insuline.

Info

Publication number
DZ2539A1
DZ2539A1 DZ980149A DZ980149A DZ2539A1 DZ 2539 A1 DZ2539 A1 DZ 2539A1 DZ 980149 A DZ980149 A DZ 980149A DZ 980149 A DZ980149 A DZ 980149A DZ 2539 A1 DZ2539 A1 DZ 2539A1
Authority
DZ
Algeria
Prior art keywords
treatment
pharmaceutical compositions
insulin resistance
insulin
resistance
Prior art date
Application number
DZ980149A
Other languages
English (en)
Inventor
Philip Albert Carpino
Charles Kwok-Fung Chiu
Bruce Allen Lefker
Lydia Codetta Pan
Judith Lee Tradeway
Michael Paul Zawistoski
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DZ2539A1 publication Critical patent/DZ2539A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
DZ980149A 1997-06-25 1998-06-24 Compositions pharmaceutiques pour le traitement dela résistance à l'insuline. DZ2539A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5079097P 1997-06-25 1997-06-25

Publications (1)

Publication Number Publication Date
DZ2539A1 true DZ2539A1 (fr) 2003-02-08

Family

ID=21967444

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ980149A DZ2539A1 (fr) 1997-06-25 1998-06-24 Compositions pharmaceutiques pour le traitement dela résistance à l'insuline.

Country Status (40)

Country Link
US (3) US6448263B1 (fr)
EP (1) EP1000085B1 (fr)
JP (2) JP2000514099A (fr)
KR (1) KR20010014224A (fr)
CN (2) CN1152049C (fr)
AP (1) AP1145A (fr)
AR (1) AR012256A1 (fr)
AT (1) ATE305477T1 (fr)
AU (1) AU747510B2 (fr)
BG (1) BG104008A (fr)
BR (1) BR9810477A (fr)
CA (1) CA2294464A1 (fr)
CO (1) CO4950621A1 (fr)
DE (1) DE69831745T2 (fr)
DZ (1) DZ2539A1 (fr)
EA (1) EA002089B1 (fr)
EG (1) EG21712A (fr)
ES (1) ES2248899T3 (fr)
HN (1) HN1998000088A (fr)
HR (1) HRP980361A2 (fr)
HU (1) HUP0001922A3 (fr)
ID (1) ID24345A (fr)
IL (7) IL154116A0 (fr)
IN (1) IN189724B (fr)
IS (1) IS5275A (fr)
MA (1) MA24581A1 (fr)
NO (1) NO996205L (fr)
NZ (1) NZ500655A (fr)
OA (1) OA11242A (fr)
PA (1) PA8452601A1 (fr)
PE (1) PE105399A1 (fr)
PL (1) PL337659A1 (fr)
SK (1) SK175699A3 (fr)
TN (1) TNSN98113A1 (fr)
TR (1) TR199903257T2 (fr)
TW (1) TW553943B (fr)
UA (1) UA64751C2 (fr)
WO (1) WO1998058949A1 (fr)
YU (1) YU70199A (fr)
ZA (1) ZA985546B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
US6541634B2 (en) * 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
US7721948B1 (en) * 1999-05-25 2010-05-25 Silverbrook Research Pty Ltd Method and system for online payments
EP1132388A3 (fr) * 2000-03-09 2004-03-03 Pfizer Products Inc. Métabolites de hexahydropyrazolo[4,3-c]pyridines
ATE446758T1 (de) 2000-05-31 2009-11-15 Pfizer Prod Inc Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
WO2004027064A2 (fr) * 2002-09-18 2004-04-01 Centre Hospitalier De L'universite De Montreal (Chum) Analogues de ghrh
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
EP1828480B1 (fr) * 2004-12-21 2014-05-21 Hercules Incorporated Resines cationiques reactives en tant qu'agents de resistance au mouille et au sec dans des systemes de fabrication de papier contenant des ions de sulfite
US20070024388A1 (en) * 2005-07-27 2007-02-01 Hassan Tanbakuchi Slabline structure with rotationally offset ground
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
KR20090107088A (ko) 2007-02-09 2009-10-12 트랜자임 파르마 인크 거대고리 그렐린 수용체 조절제 및 이의 사용 방법
US7862825B2 (en) * 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
RU2403902C1 (ru) * 2009-06-15 2010-11-20 Илья Николаевич Медведев Способ снижения биологического возраста при нарушении толерантности к глюкозе
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
JP2015525202A (ja) 2012-05-03 2015-09-03 ノバルティス アーゲー グレリン受容体アゴニストとしての２，７−ジアザ−スピロ［４，５］デカ−７−イル誘導体のｌ−リンゴ酸塩およびその結晶形態
WO2014192294A1 (fr) * 2013-05-28 2014-12-04 Raqualia Pharma Inc. Formes polymorphes
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
RU2695649C2 (ru) * 2014-08-05 2019-07-25 Раквалиа Фарма Инк. Производные серина в качестве агонистов грелиновых рецепторов
EP3212648A1 (fr) * 2014-10-31 2017-09-06 RaQualia Pharma Inc. Dérivés tétrahydropyrazolopyridines utiles en tant qu'agonistes du récepteur de la ghréline
WO2017075535A1 (fr) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Méthodes de traitement de troubles neurodégénératifs
CN120265641A (zh) * 2023-04-21 2025-07-04 长春金赛药业有限责任公司 GHSR 1a激动剂、药物组合物及其制备方法和应用
CN119285632A (zh) * 2024-10-09 2025-01-10 威海中腾医药科技有限公司 一种基于酵母醇脱氢酶催化氧化的卡普瑞林中间体的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3235550A (en) 1966-02-15 Anal g gesiaxoat t tail intravenous injection
US3202660A (en) 1961-10-09 1965-08-24 Boehringer Sohn Ingelheim Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
GB2101114B (en) 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
US5242783A (en) 1991-07-31 1993-09-07 Eastman Kodak Company Photographic material and process
EP0669830A4 (fr) 1992-11-06 1997-02-26 Merck & Co Inc Analogues dipeptidiques substitues favorisant la liberation de l'hormone de croissance.
NZ258412A (en) 1992-12-11 1997-01-29 Merck & Co Inc Spiro-fused piperidine derivatives and pharmaceutical compositions
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
PL322706A1 (en) 1993-11-09 1998-02-16 Merck & Co Inc Piperidines, pyrolidines and hexahydro-1h-azepins enhancing growth hormone liberation
BR9610277A (pt) 1995-08-31 1999-07-06 Schering Corp Derivados de piperazino como antagonistas de neurowuinina
EP0766966A3 (fr) 1995-09-08 2001-02-28 Eli Lilly And Company Méthode de traitement de la résistance à l'insuline
WO1997023508A1 (fr) 1995-12-22 1997-07-03 Novo Nordisk A/S Composes avec des proprietes de liberation de l'hormone de croissance
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
US6251902B1 (en) * 1997-06-25 2001-06-26 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)

Also Published As

Publication number Publication date
AP1145A (en) 2003-02-14
CO4950621A1 (es) 2000-09-01
DE69831745D1 (de) 2006-02-09
HK1028051A1 (en) 2001-02-02
CN1530107A (zh) 2004-09-22
AU7445698A (en) 1999-01-04
IL133626A0 (en) 2001-04-30
EP1000085B1 (fr) 2005-09-28
AR012256A1 (es) 2000-09-27
NO996205D0 (no) 1999-12-15
EP1000085A1 (fr) 2000-05-17
SK175699A3 (en) 2001-04-09
JP2000514099A (ja) 2000-10-24
US6630487B2 (en) 2003-10-07
KR20010014224A (ko) 2001-02-26
IN189724B (fr) 2003-04-19
EG21712A (en) 2002-02-27
BR9810477A (pt) 2007-05-22
EA199901075A1 (ru) 2000-08-28
CN1152049C (zh) 2004-06-02
NO996205L (no) 1999-12-15
CA2294464A1 (fr) 1998-12-30
US20030100561A1 (en) 2003-05-29
US6448263B1 (en) 2002-09-10
HUP0001922A3 (en) 2001-02-28
HN1998000088A (es) 1999-01-08
TR199903257T2 (xx) 2000-12-21
ID24345A (id) 2000-07-13
TW553943B (en) 2003-09-21
IS5275A (is) 1999-11-26
ZA985546B (en) 2000-01-10
IL154116A0 (en) 2003-07-31
YU70199A (sh) 2003-01-31
IL156465A0 (en) 2004-01-04
WO1998058949A1 (fr) 1998-12-30
PL337659A1 (en) 2000-08-28
IL154115A0 (en) 2003-07-31
US6867202B1 (en) 2005-03-15
EA002089B1 (ru) 2001-12-24
DE69831745T2 (de) 2006-08-31
IL154114A0 (en) 2003-07-31
TNSN98113A1 (fr) 2005-03-15
JP2005097261A (ja) 2005-04-14
UA64751C2 (uk) 2004-03-15
HUP0001922A2 (hu) 2000-12-28
IL154112A0 (en) 2003-07-31
OA11242A (en) 2003-07-23
AP9801267A0 (en) 1998-06-30
PE105399A1 (es) 1999-11-04
NZ500655A (en) 2002-02-01
BG104008A (en) 2000-07-31
ES2248899T3 (es) 2006-03-16
ATE305477T1 (de) 2005-10-15
AU747510B2 (en) 2002-05-16
IL154111A0 (en) 2003-07-31
JP3742643B2 (ja) 2006-02-08
MA24581A1 (fr) 1998-12-31
IL156465A (en) 2004-07-25
HRP980361A2 (en) 1999-02-28
CN1259140A (zh) 2000-07-05
PA8452601A1 (es) 2000-05-24

Similar Documents

Publication Publication Date Title
DZ2539A1 (fr) Compositions pharmaceutiques pour le traitement dela résistance à l'insuline.
DZ2494A1 (fr) Composition pharmaceutique d'oméprazole.
ITRM910696A1 (it) Composizioni farmaceutiche per l'applicazione per via nasale.
FI965154L (fi) Lääkkeen paksusuoleen kuljettava koostumus
FR2705566B1 (fr) Nouvelles compositions pharmaceutiques.
DZ2752A1 (fr) Composés et compositions pharmaceutiques pour le traitement du paludisme.
NO20006630D0 (no) Farmasöytisk sammensetning for behandlingen av diabetes
FI973828A0 (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
FI20071025L (fi) Farmaseuttisia koostumuksia
DZ3191A1 (fr) Composés d'indazole et compositions pharmaceutiques inhibant les protéines kinases, et procédés d'utilisation de ceux-ci.
FI20000720L (fi) Pitkitettyyn vapautumiseen perustuva tablettiformulaatio Parkisonin taudin hoitamiseksi
IT1246983B (it) L-2'-desossiuridine e composizioni farmaceutiche che le contengono.
IT1295645B1 (it) Apparecchio per l'elettroemanazione di principi attivi.
FR2687573B1 (fr) Composition pour application nasale.
EP0601058A4 (fr) Formulations transdermiques pour l'administration de prazosine.
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
RU98116126A (ru) Фармацевтический комбинированный препарат из ингибитора натрий-водородного обмена и лекарственных средств для лечения сердечно-сосудистых заболеваний
FR2753376B1 (fr) Compositions pharmaceutiques comprenant de l'amisulpride et leurs applications therapeutiques
NO950134D0 (no) Formuleringer for oralt administrerte farmasöytiske midler
BR9507768A (pt) Composição farmacêutica
FR2758465B1 (fr) Composition pour le traitement de l'amiante
DZ2564A1 (fr) Compositions pharmaceutiques pour le traitement dudiabète sucre et d'états associés.
BR9806083A (pt) Composi-Æo farmac-utica para o tratamento da hapattite c
FR2695297B1 (fr) Composition d'agent désinfectant.
FR2718024B1 (fr) Médicament et composition pharmaceutique pour le traitement de l'inflammation.